Back to Portfolio
Visit Website
HVR Cardio
MedTechCatheter-based mitral valve repair with breakthrough helix technology.
CardiovascularCatheterFDA BreakthroughMinimally Invasive
Invested
2021
Founded
2009
Headquarters
Helsinki, Finland
Sector
MedTech
About
HVR Cardio develops CathHELIX, a catheter-based device for mitral valve repair that has received FDA Breakthrough Device Designation. The device reduces the mitral annulus and deploys a self-securing ring to restore native leaflet function, offering a minimally invasive treatment for mitral regurgitation with Series B funding secured.